MultiCell Technologies Files Milestone Patent to Treat Cancer.Proprietary Technology Applies Company's Immune-Based Therapeutics to Target Malignant Tumors in Potential Multibillion-Dollar Markets SAN DIEGO -- MultiCell Technologies, Inc. [OTCBB OTCBB See OTC Bulletin Board (OTCBB). : MCET MCET Massachusetts Corporation for Educational Telecommunications MCET Maryland Center for Environmental Training MCET Micro-Computer Electronics Technology MCET Michigan Consumer Evaluation Team, Inc ], developing first-in-class drugs based on advanced immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system. MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The new patent filing broadens protection of MultiCell's intellectual property portfolio, and further expands the Company's potential therapeutic development targets to include cancer. The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR TLR Trailer TLR Toll Like Receptor (immunological research) TLR Temple (University) Law Review TLR Twin Lens Reflex TLR Texas Law Review TLR The Last Resort (gaming clan) ) technology platform to combat malignant tumors in human patients. "The implications for this patent-pending technology are far-reaching and could someday help treat the millions of patients suffering from various cancers," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics." The Company's technology platforms include TLR and T-cell targeting to modulate both the innate and adaptive immune systems, thus enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting. MultiCell's new patent provides a method for treatment of a tumor after clinical diagnosis. The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope epitope: see immunity. attached to an IgG backbone to form an Ig-peptide molecule followed by administration of the Ig-peptide molecule in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. in conjunction with MultiCell's dsRNA TLR therapeutic. MultiCell has a therapeutic pipeline with drug candidates already in various advanced stages of human clinical trials. These therapies include: * MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world. * MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath myelin sheath n. The insulating envelope of myelin that surrounds the core of a nerve fiber or axon and that facilitates the transmission of nerve impulses, formed from the cell membrane of the Schwann cell in the peripheral nervous system and from of nerve cells. MCT-175 successfully ameliorated the disease in animal models. * MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models. * MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. successfully reduced pulmonary influenza virus influenza virus n. Any of three viruses of the genus Influenzavirus designated type A, type B, and type C, that cause influenza and influenzalike infections. levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. in animal models. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion